Key facts
- Transcera’s last known valuation is $14.3M (Jun 2023).
- It has raised $5.4M across 1 recorded rounds; the latest was Seed Round ($1.0M) in Jul 2021.
- Notable investors include MassChallenge, Harvard Innovation Launch Lab, Pear (California), Tau Ventures, Digitalis Ventures — 9 tracked in total.
- Transcera has filed 2 Form Ds with the SEC, most recently Nov 2021 ($10K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Transcera
Funding rounds
1 roundsAbout Transcera
Developer of a lipid-based drug delivery system, designed to improve the treatment of chronic diseases. The company offers a novel delivery platform that enables large therapeutic molecules to cross cellular barriers and enhances absorption and pharmacokinetics, enabling healthcare professionals to achieve more precise and effective targeting of therapeutics for patients with chronic conditions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2020
- Employees
- 6
- Website
- transcera.com/
- Ownership
- Privately Held (backing)
Transcera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Transcera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Transcera in its N-PORT filings yet. We sweep new filings monthly.